These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25437499)

  • 1. Bleeding and the new anticoagulants: strategies and concerns.
    Samama CM; Levy JH
    Anesthesiology; 2015 Feb; 122(2):236-7. PubMed ID: 25437499
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
    Hoffman M; Volovyk Z; Monroe DM
    Anesthesiology; 2015 Feb; 122(2):353-62. PubMed ID: 25502064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of new oral anticoagulants.
    Battinelli EM
    Circulation; 2011 Oct; 124(14):1508-10. PubMed ID: 21969317
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of an antagonist to reverse the action of dabigatran.
    Jolobe OM
    QJM; 2012 Feb; 105(2):212-4. PubMed ID: 22052956
    [No Abstract]   [Full Text] [Related]  

  • 6. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
    Grottke O; van Ryn J; Spronk HM; Rossaint R
    Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
    Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
    Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
    Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
    Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter by Bernstein et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Bernstein RA; Alberts MJ; Garcia DA
    Circulation; 2012 Apr; 125(16):e614; author reply e616. PubMed ID: 22529072
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter by Marlu et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects".
    Marlu R; Hodaj E; Pernod G
    Circulation; 2012 Apr; 125(16):e615; author reply e616. PubMed ID: 22529073
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
    Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
    Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
    Na SY; Mracsko E; van Ryn J; Veltkamp R
    Ann Neurol; 2015 Jul; 78(1):137-41. PubMed ID: 25899749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking direct inhibitor bleeding.
    Millar CM; Lane DA
    Blood; 2013 May; 121(18):3543-4. PubMed ID: 23640994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.
    Pragst I; Zeitler SH; Doerr B; Kaspereit FJ; Herzog E; Dickneite G; van Ryn J
    J Thromb Haemost; 2012 Sep; 10(9):1841-8. PubMed ID: 22812619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oral thrombin inhibitor dabigatran: strengths and weaknesses.
    Schulman S; Majeed A
    Semin Thromb Hemost; 2012 Feb; 38(1):7-15. PubMed ID: 22314598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Augoustides JG
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):1208-12. PubMed ID: 21982327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.
    Sadeghi N; Kahn D; Jeske W; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2013; 19(6):589-99. PubMed ID: 23463187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.